Gateway to Think Tanks
来源类型 | Working Paper |
规范类型 | 报告 |
DOI | 10.3386/w14932 |
来源ID | Working Paper 14932 |
What's the \"Interest\" in FDA Drug Advisory Committee Conflicts of Interest? | |
Joseph Golec; John Vernon | |
发表日期 | 2009-04-30 |
出版年 | 2009 |
语种 | 英语 |
摘要 | Food and Drug Administration (FDA) drug advisory committee members sometimes have financial interests tied to drug companies. Congress and the public have become concerned that these financial interests lead to conflicts of interest. They conclude that the conflicts bias committee recommendations, and lead to unsafe or ineffective drugs being approved for public consumption, or, conversely, delays in approval of safe and effective drugs. Our paper provides empirical evidence, based on an event study methodology, that advisory committee meetings lead to weak or statistically insignificant effects on stock prices and hence equity values of regulated companies assumed to be affected by the particular matters coming before committee meetings. |
主题 | Financial Economics ; Financial Markets ; Corporate Finance ; Health, Education, and Welfare ; Health ; Education |
URL | https://www.nber.org/papers/w14932 |
来源智库 | National Bureau of Economic Research (United States) |
引用统计 | |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/572608 |
推荐引用方式 GB/T 7714 | Joseph Golec,John Vernon. What's the \"Interest\" in FDA Drug Advisory Committee Conflicts of Interest?. 2009. |
条目包含的文件 | ||||||
文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
w14932.pdf(121KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[Joseph Golec]的文章 |
[John Vernon]的文章 |
百度学术 |
百度学术中相似的文章 |
[Joseph Golec]的文章 |
[John Vernon]的文章 |
必应学术 |
必应学术中相似的文章 |
[Joseph Golec]的文章 |
[John Vernon]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。